AQR Capital Management
AIMT

AQR Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

AQR Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17,355
Closed -$473K – 2320
2018
Q3 		$473K Sell
17,355
-56
-0.3% -$1.58K ﹤0.01% 1975
2018
Q2 		$468K Hold
17,411
– – ﹤0.01% 1996
2018
Q1 		$554K Buy
17,411
+4,698
+37% +$165K ﹤0.01% 1876
2017
Q4 		$481K Sell
12,713
-16,965
-57% -$547K ﹤0.01% 1929
2017
Q3 		$736K Buy
29,678
+15,582
+111% +$336K ﹤0.01% 1786
2017
Q2 		$290K Buy
+14,096
New +$269K ﹤0.01% 2048

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

AQR Capital Management's AIMT Position: Q4 2018 in Review

AQR Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2018, closing a stake of 17,355 shares — an estimated $473K sold.

AQR Capital Management first reported a position in AIMT in Q2 2017 and held it in 6 quarters. The position peaked at $736K in Q3 2017. 132 funds tracked by Wall St. Rank hold AIMT as of Q4 2018.

  • AQR Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • AQR Capital Management sold 17,355 Aimmune Therapeutics shares in Q4 2018, an estimated $473K.
  • AQR Capital Management first reported a position in Aimmune Therapeutics in Q2 2017 and held it in 6 quarters.
  • AQR Capital Management's Aimmune Therapeutics position peaked at $736K in Q3 2017.
  • 132 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2018.

Based on AQR Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.